Skip to main content
. 2022 Mar 22;13:853572. doi: 10.3389/fimmu.2022.853572

Figure 1.

Figure 1

Experimental and analytical workflow. Peripheral whole blood samples were collected from active TB patients (n = 22) throughout treatment (T0: baseline. T1: T0 + 2 months. T2: end of treatment). After whole blood stimulation with Mtb antigens (TB2 and rmsHBHA) or with a negative control (NIL), total white blood cells were extracted. After palladium (Pd) barcoding for unique sample identification before multiplexing, T-cells were analyzed with a 29-marker mass cytometry panel. TB2, Qiagen QuantiFERON TB2 tube (ESAT-6 + CFP-10 + undisclosed CD8+ T-cell stimulating peptide pool); rmsHBHA, recombinant heparin-binding hemagglutinin obtained in Mycobacterium smegmatis; UMAP, Uniform Manifold Approximation and Projection; FlowSOM, self-organizing map.